Gismo Therapeutics Inc. has been awarded two grants to continue their development of therapies to treat Parkinson’s Disease. A $384,000 SBIR grant entitled “Glycosaminoglycan-Interacting Small Molecule (GISMO) as Parkinson’s Therapeutic” was awarded by the National Institute of Neurological Disorders and Stroke (NINDS) – NIH. In addition to this, Gismo Therapeutics also received a $150,000 Kentucky SBIR Matching Funds grant from Kentucky Cabinet for Economic Development.
The funds will allow the company to investigate therapeutics directed against a newly identified disease pathway in Parkinson’s. Gismo Therapeutics plans to leverage its expertise in small-molecule compounds that target glycosaminoglycans (GISMOs). Glycosaminoglycans have been identified as key molecules in the disease process, by promoting the internalization of amyloid peptides into nerve cells and spreading through nervous system, advancing the disease. By intervening with its purpose-designed GISMO compounds, the company aims to mitigate the disease progression.
Under the NINDS grant, the company is collaborating with the team of Patrik Brundin, M.D., Ph.D., the Jay Van Andel Endowed Chair in Parkinson’s Research and Director of the Center for Neurodegenerative Science at Van Andel Research Institute (VARI) in Grand Rapids, MI.
“We are pleased to have been awarded these two grants to identify new therapeutics for the treatment of Parkinson’s disease,” said Paul Gregor, Ph.D., company founder and GISMO technology inventor. “These funds will allow the company to advance its program from the drug discovery phase to preclinical development, with the aim of initiating IND-enabling studies in 2018.”
Gismo Therapeutics Inc. is a biotech start-up company targeting fundamental biochemical processes that are at the root cause of Alzheimer’s and Parkinson’s Disease pathogenesis. They are currently developing first-in-class, disease-modifying oral therapeutics for the treatment of both Alzheimer’s Disease, and Parkinson’s Disease.
For more information about Gismo Therapeutics Inc., please visit their website.